These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28124511)

  • 81. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 May; 36(5):651-8. PubMed ID: 26616353
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders.
    Wiegand J; Schiefke I; Stein K; Berg T; Kullig U; Ende K
    Hamostaseologie; 2017 May; 37(2):127-130. PubMed ID: 27416915
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
    Omata M; Nishiguchi S; Ueno Y; Mochizuki H; Izumi N; Ikeda F; Toyoda H; Yokosuka O; Nirei K; Genda T; Umemura T; Takehara T; Sakamoto N; Nishigaki Y; Nakane K; Toda N; Ide T; Yanase M; Hino K; Gao B; Garrison KL; Dvory-Sobol H; Ishizaki A; Omote M; Brainard D; Knox S; Symonds WT; McHutchison JG; Yatsuhashi H; Mizokami M
    J Viral Hepat; 2014 Nov; 21(11):762-8. PubMed ID: 25196837
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
    Modi AA; Nazario H; Trotter JF; Gautam M; Weinstein J; Mantry P; Barnes M; Habib A; McAfee J; Teachenor O; Tujague L; Gonzalez S
    Liver Transpl; 2016 Mar; 22(3):281-6. PubMed ID: 26335142
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
    Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Henry L; Hunt S
    J Viral Hepat; 2016 Nov; 23(11):857-865. PubMed ID: 27291391
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
    Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES
    Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System.
    Lai JB; Witt MA; Pauly MP; Ready J; Allerton M; Seo S; Witt DJ
    Drugs; 2017 Mar; 77(3):313-318. PubMed ID: 28078644
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
    Younossi ZM; Elsheikh E; Stepanova M; Gerber L; Nader F; Stamm LM; Brainard DM; McHutchinson JG
    J Viral Hepat; 2015 Dec; 22(12):977-82. PubMed ID: 26280786
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
    Everson GT; Towner WJ; Davis MN; Wyles DL; Nahass RG; Thuluvath PJ; Etzkorn K; Hinestrosa F; Tong M; Rabinovitz M; McNally J; Brainard DM; Han L; Doehle B; McHutchison JG; Morgan T; Chung RT; Tran TT
    Ann Intern Med; 2015 Dec; 163(11):818-26. PubMed ID: 26551051
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

  • 91. COMBINED NS5A & NS5B NUCLEOTIDE INHIBITOR THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C WITH STAGE 5 CHRONIC KIDNEY DISEASE ON HEMODIALYSIS.
    Debnath P; Chandnani S; Rathi P; Nair S; Pawar V; Contractor Q
    Arq Gastroenterol; 2020; 57(1):39-44. PubMed ID: 32294734
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.
    El-Khayat HR; Kamal EM; El-Sayed MH; El-Shabrawi M; Ayoub H; RizK A; Maher M; El Sheemy RY; Fouad YM; Attia D
    Aliment Pharmacol Ther; 2018 Mar; 47(6):838-844. PubMed ID: 29349793
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection.
    Stedman CAM; Hyland RH; Ding X; Pang PS; McHutchison JG; Gane EJ
    Haemophilia; 2016 Mar; 22(2):214-217. PubMed ID: 26315711
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
    Younossi ZM; Stepanova M; Afdhal N; Kowdley KV; Zeuzem S; Henry L; Hunt SL; Marcellin P
    J Hepatol; 2015 Aug; 63(2):337-45. PubMed ID: 25795586
    [TBL] [Abstract][Full Text] [Related]  

  • 95. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
    Zeuzem S; Mizokami M; Pianko S; Mangia A; Han KH; Martin R; Svarovskaia E; Dvory-Sobol H; Doehle B; Hedskog C; Yun C; Brainard DM; Knox S; McHutchison JG; Miller MD; Mo H; Chuang WL; Jacobson I; Dore GJ; Sulkowski M
    J Hepatol; 2017 May; 66(5):910-918. PubMed ID: 28108232
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.
    Johnson SW; Davis MM; Stever LM; Priest DH
    J Clin Pharm Ther; 2016 Dec; 41(6):727-729. PubMed ID: 27670742
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients.
    Sawinski D; Lee DH; Doyle AM; Blumberg EA
    Transplantation; 2017 May; 101(5):974-979. PubMed ID: 27467534
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).
    Golabi P; Elsheikh E; Karrar A; Estep JM; Younossi I; Stepanova M; Gerber L; Younossi ZM
    Medicine (Baltimore); 2016 Nov; 95(46):e5066. PubMed ID: 27861337
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
    Zeuzem S; Dusheiko GM; Salupere R; Mangia A; Flisiak R; Hyland RH; Illeperuma A; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Weiland O; Reesink HW; Ferenci P; Hézode C; Esteban R;
    N Engl J Med; 2014 May; 370(21):1993-2001. PubMed ID: 24795201
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation.
    Oya Y; Sugawara Y; Watanabe T; Yoshimaru Y; Honda M; Hashimoto S; Yoshii D; Isono K; Hayashida S; Yamamoto H; Tanaka M; Sasaki Y; Inomata Y
    Biosci Trends; 2017 Jan; 10(6):496-499. PubMed ID: 27990005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.